Prognosis in amyotrophic lateral sclerosis: A population-based study

Neurology

Volumn 60, Issue 5, 2003, Pages 813-819

  Del Aguila, M A ^a   Longstreth Jr , W T ^a,b   McGuire, V ^a   Koepsell, T D ^a   Van Belle, G ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; NONBIOLOGICAL MODEL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; UNITED STATES;

EID: 0037432266     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000049472.47709.3B     Document Type: Article

References (61)

1. Kristensen O, Melgaard B. Motor neuron disease. Prognosis and epidemiology. Acta Neurol Scand 1977;56:299-308.
2. Juergens SM, Kurland LT, Okazaki H, Mulder DW. ALS in Rochester, Minnesota, 1925-1977. Neurology 1980;30:463-470.
3. Forsgren L, Almay BG, Holmgren G, Wall S. Epidemiology of motor neuron disease in northern Sweden. Acta Neurol Scand 1983;68:20-29.
4. Murros K, Fogelholm R. Amyotrophic lateral sclerosis in Middle-Finland: an epidemiological study. Acta Neurol Scand 1983;67:41-47.
5. Gunnarsson L-G. Motor neuron disease and heavy manual labor: an epidemiologic survey of Vsbrmland County, Sweden. Neuroepidemiology 1984;3:195-206.
6. Mortara P, Chio A, Rosso MG, Leone M, Schiffer D. Motor neuron disease in the province of Turin, Italy, 1966 -1980. Survival analysis in an unselected population. J Neurol Sci 1984;66:165-173.
7. Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y. Amyotrophic lateral sclerosis. A study of its presentation and prognosis. J Neurol 1985;232:295-300.
8. Yoshida S, Mulder DW, Kurland LT, Chu CP, Okazaki H. Follow-up study on amyotrophic lateral sclerosis in Rochester, Minn., 1925 through 1984. Neuroepidemiology 1986;5:61-70.
9. Granieri E, Carreras M, Tola R, et al. Motor neuron disease in the province of Ferrara, Italy, in 1964-1982. Neurology 1988;38:1604-1608.
10. Scarpa M, Colombo A, Panzetti P, Sorgato P. Epidemiology of amyotrophic lateral sclerosis in the province of Modena, Italy. Influence of environmental exposure to lead. Acta Neurol Scand 1988;77:456-460.
11. Salemi G, Fierro B, Arcara A, Cassata M, Castiglione MG, Savettieri G. Amyotrophic lateral sclerosis in Palermo, Italy: an epidemiological study. Ital J Neurol Sci 1989;10:505-509.
12. Christensen PB, Hojer-Pedersen E, Jensen NB. Survival of patients with amyotrophic lateral sclerosis in 2 Danish counties. Neurology 1990;40:600-604.
13. Chancellor AM, Slattery JM, Fraser H, Swingler RJ, Holloway SM, Warlow CP. The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register. J Neurol 1993;240:339-346.
14. Norris F, Shepherd R, Denys E, et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci 1993;118:48-55.
15. Tysnes OB, Vollset SE, Larsen JP, Aarli JA. Prognostic factors and survival in amyotrophic lateral sclerosis. Neuroepidemiology 1994;13:226-235.
16. Bettoni L, Bazzani M, Bortone E, Dascola I, Pisani E, Mancia D. Steadiness of amyotrophic lateral sclerosis in the province of Parma, Italy, 1960-1990. Acta Neurol Scand 1994;90:276-280.
17. Lee JR, Annegers JF, Appel SH. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 1995;132:207-215.
18. Forbes RB, Colville S, Parratt J, Chancellor A, Davenport R, Swingler RJ. Ten year survival data from the Scottish MND Registry. J Neurol Neurosurg Psychiatry 2002;73:217. Abstract.
19. Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology 2002;59:280-282.
20. Hillel AD, Miller R. Bulbar amyotrophic lateral sclerosis: patterns of progression and clinical management. Head Neck 1989;11:51-59.
21. McDonald ER, Wiedenfeld SA, Hillel A, Carpenter CL, Walter RA. Survival in amyotrophic lateral sclerosis. The role of psychological factors. Arch Neurol 1994;51:17-23.
22. Mackay RP. Course and prognosis in amyotrophic lateral sclerosis. Arch Neurol 1963;8:117-127.
23. Boman K, Meurman T. Prognosis of amyotrophic lateral sclerosis. Acta Neurol Scand 1967;43:489-498.
24. Mulder DW, Howard FM Jr. Patient resistance and prognosis in amyotrophic lateral sclerosis. Mayo Clin Proc 1976;51:537-541.
25. Rosen AD. Amyotrophic lateral sclerosis. Clinical features and prognosis. Arch Neurol 1978;35:638-642.
26. Schiffer D, Brignolio F, Chio A, Leone M, Rosso MG. A study of prognostic factors in motor neuron disease. Adv Exp Med Biol 1987;209:255-263.
27. Munsat TL, Andres PL, Finison L, Conlon T, Thibodeau L. The natural history of motoneuron loss in amyotrophic lateral sclerosis. Neurology 1988;38:409-413.
28. Jablecki CK, Berry C, Leach J. Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve 1989;12:833-841.
29. Eisen A, Schulzer M, MacNeil M, Pant B, Mak E. Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve 1993;16:27-32.
30. Ringel SP, Murphy JR, Alderson MK, et al. The natural history of amyotrophic lateral sclerosis. Neurology 1993;43:1316-1322.
31. Pradas J, Finison L, Andres PL, Thornell B, Hollander D, Munsat TL. The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology 1993;43:751-755.
32. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995;118:707-719.
33. Preux PM, Couratier P, Boutros-Toni F, et al. Survival prediction in sporadic amyotrophic lateral sclerosis. Age and clinical form at onset are independent risk factors. Neuroepidemiology 1996;15:153-160.
34. Louwerse ES, Visser CE, Bossuyt PM, Weverling GJ. Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS Consortium J Neurol Sci 1997;152(suppl 1):S10-17.
35. Kondo K, Hemmi L. Clinical statistics in 515 fatal cases of motor neuron disease. Determinants of course. Neuroepidemiology 1984;3:129-148.
36. Uebayashi Y, Yase Y, Tanaka H, Shimada Y, Toyokura Y. Prognosis of motor neuron disease in Japan. Neuroepidemiology 1983;2:243-256.
37. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group N Engl J Med 1994;330:585-591.
38. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347:1425-1431.
39. Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. Neurology 1998;50:66-72.
40. McGuire V, Longstreth WT Jr, Koepsell TD, van Belle G. Incidence of amyotrophic lateral sclerosis in three counties in western. Washington state. Neurology 1996;47:571-573.
41. McGuire V, Longstreth WT Jr, Nelson LM, et al. Occupational exposures and amyotrophic lateral sclerosis. A population- based case-control study. Am J Epidemiol 1997;145:1076-1088.
42. Longstreth WT Jr, McGuire V, Koepsell TD, Wang Y, van Belle G. Risk of amyotrophic lateral sclerosis and history of physical activity: a population-based case-control study. Arch Neurol 1998;55:201-206.
43. Cruz DC, Nelson LM, McGuire V, Longstreth WT Jr. Physical trauma and family history of neurodegenerative diseases in amyotrophic lateral sclerosis: a population-based case-control study. Neuroepidemiology 1999;18:101-110.
44. Nelson LM, Matkin C, Longstreth WT Jr, McGuire V. Population-based case-control study of amyotrophic lateral sclerosis in western Washington state. II. Diet. Am J Epidemiol 2000;151:164-173.
45. Nelson LM, McGuire V, Longstreth WT Jr, Matkin C. Population-based case-control study of amyotrophic lateral sclerosis in western Washington state. I. Cigarette smoking and alcohol consumption. Am J Epidemiol 2000;151:156-163.
46. Hillel AD, Miller RM, Yorkston K, McDonald E, Norris FH, Konikow N. Amyotrophic lateral sclerosis severity scale. Neuroepidemiology 1989;8:142-150.
47. Hillel AD, Yorkston K, Miller RM. Using phonation time to estimate vital capacity in amyotrophic lateral sclerosis. Arch Phys Med Rehabil 1989;70:618-620.
48. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. Boston: The Health Institute, New England Medical Center, 1993.
49. Ware JE Jr, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user's manual. Boston: The Health Institute, New England Medical Center, 1994.
50. Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995;33:AS264-279.
51. Breslow NE, Day NE. Statistical methods in cancer research, Volume II-The design and analysis of cohort studies. IARC Sci Publ 1987;82:1-406.
52. Norusis M. SPSS for Windows. Chicago: SPSS Inc., 1993.
53. Breiman L, Friedman J, Olshen R, Charles S. Classification and regression trees. Pacific Grove: Wadsworth, 1984.
54. Nelson LM, Bloch DA, Longstreth WT Jr, Shi H. Recursive partitioning for the identification of disease risk subgroups: a case-control study of subarachnoid hemorrhage. J Clin Epidemiol 1998;51:199-209.
55. Steinberg D, Colla P. CART. Tree-structured non-parametric data analysis. San Diego, CA: Salford Systems, 1995.
56. Schiffman PL, Belsh JM. Pulmonary function at diagnosis of amyotrophic lateral sclerosis. Rate of deterioration. Chest 1993;103:508-513.
57. Young CA, Tedman BM, Williams IR. Disease progression and perceptions of health in patients with motor neurone disease. J Neurol Sci 1995;129(suppl):50-53.
58. Shields RK, Ruhland JL, Ross MA, Saehler MM, Smith KB, Heffner ML. Analysis of health-related quality of life and muscle impairment in individuals with amyotrophic lateral sclerosis using the medical outcome survey and the Tufts Quantitative Neuromuscular Exam. Arch Phys Med Rehabil 1998;79:855-862.
59. Davis VL, Armon C, Britt WG, III, et al. A new, short, subjective, disease-specific, quality-of-life scale for patients with ALS - the ALSQOL-11: a cross-sectional validation study. Neurology 1999;52(suppl 2):A527. Abstract.
60. Hein H, Schucher B, Magnussen H. Intermittent assisted ventilation in neuromuscular diseases: course and quality of life. Pneumologie 1999;53(suppl 2):S89-S90.
61. Jenkinson C, Hobart J, Chandola T, Fitzpatrick R, Peto V, Swash M. Use of the short form health survey (SF-36) in patients with amyotrophic lateral sclerosis: tests of data quality, score reliability, response rate and scaling assumptions. J Neurol 2002;249:178-183.